News | Digital Pathology | July 16, 2019

Paige Announces Clinical-grade Artificial Intelligence in Pathology

Article published in Nature Medicine provides further scientific evidence for deployment of computational decision support systems to improve patient care

Paige Announces Clinical-grade Artificial Intelligence in Pathology

July 16, 2019 — Computational pathology company Paige announced the publication of an article in Nature Medicine describing an artificial intelligence (AI) system for computational pathology that achieves clinical-grade accuracy levels. The paper provides further scientific evidence that pathologists’ work in diagnosing and treating cancer can be complemented and aided through the deployment of computational decision-support systems to improve patient care.

The team of scientists responsible for the work described in the article developed specially-designed deep learning algorithms to build a system that can detect prostate cancer, skin cancer and breast cancer with near-perfect accuracy. These algorithms are based on a vast dataset of nearly 45,000 de-identified, digitized slide images from more than 15,000 cancer patients from 44 countries.

The paper outlines how a series of novel algorithms, created using datasets 10 times larger than those that have been manually curated, performed better and also are more generalizable. The significance of this new development hinges on the fact that curating datasets can be prohibitively expensive and time intensive. By eliminating the need to curate datasets, Paige can now develop many more highly accurate algorithms that can be built into clinical decision support products to help pathologists around the world drive better patient care.

Paige plans to commercialize several of these solutions to address the most pressing needs in pathology to improve patient care. The company has already built on the academic work described in Nature Medicine to develop a clinical product, based on technology currently under review by the U.S. Food and Drug Administration (FDA) as a designated Breakthrough Device, for an intended indication different than the one described in the article.

All data collection, research and analysis for this research was conducted exclusively at Memorial Sloan Kettering (MSK) in New York City. The publication of the study’s findings was the result of collaboration between numerous researchers and clinicians, and made possible by Paige’s partnership with MSK. All data were de-identified and did not contain any protected health information or label text. 

Watch the VIDEO: Integrating Digital Pathology With Radiology

For more information: www.nature.com/nm

Reference

1. Campanella G., Hanna M.G., Geneslaw L., et al. Clinical-grade Computational Pathology using Weakly Supervised Deep Learning on Whole Slide Images. Nature Medicine, July 15, 2019. https://doi.org/10.1038/s41591-019-0508-1

Related Content

Imaging Artificial Intelligence (AI) provider Qure.ai announced its first US FDA 510(k) clearance for its head CT scan product qER. The US Food and Drug Administration's decision covers four critical abnormalities identified by Qure.ai's emergency room product.
News | Artificial Intelligence | June 30, 2020
June 30, 2020 — Imaging Artificial Intelligence (AI) provider Qure.ai announced its first US FDA 510(k) clearance for
Universal digital operating system for surgery enables health tech companies and start-ups to accelerate, scale and grow

Stefan Vilsmeier, President and CEO of Brainlab Photo courtesy of Brainlab

News | Artificial Intelligence | June 26, 2020
June 26, 2020 — ...
QuEST Global, a global product engineering and lifecycle services company, announced that it has developed a robust artificial intelligence (AI)-powered solution that will enable healthcare professionals to accelerate the screening of COVID-19 patients with pneumonia symptoms.

Getty Images

News | Coronavirus (COVID-19) | June 18, 2020
June 18, 2020 — QuEST Global, a global product engineering and lifecycle services company, announced that it has deve
RapidAI acquires comprehensive aneurysm management innovator and expands scope to include aneurysm, extending its leadership in cerebrovascular imaging
News | Artificial Intelligence | June 12, 2020
June 12, 2020 — RapidAI announced the acquisition of
Clinicians can access DLCExpert online (DLCOnline) to help them manage the backlog of cases which has built up during the crisis
News | Artificial Intelligence | June 09, 2020
June 9, 2020 — Mirada Medical, a global leader in...
Lunit announced that their AI solution for chest x-ray analysis is now being used and tested in more than 10 countries for COVID-19 management, providing assistance in chest X-ray interpretation during patient triage and monitoring.

A radiologist in Hospital do Câncer de Pernambuco, located in Recife, Brazil, is examining a chest x-ray image using Lunit INSIGHT CXR.

News | Artificial Intelligence | June 08, 2020
June 8, 2020 — Lunit announced that their AI...